No abstract

No abstract

S65impact on patient quality of life due to flu-like symptoms, fatigue, and other adverse events. Sofosbuvir (SOF) is a recently approved potent NS5B-inhibitor that is welltolerated with high efficacy regardless of genotype (GT), treatment experience, or cirrhosis status. This study evaluated the health outcomes of treating CHC patients with SOF+ribavirin (R), PR, or no treatment (NT) in China. METHODS: A Markov model simulated long-term outcomes for a cohort of 10,000 CHC non-cirrhotic (NC; 36.4%) and cirrhotic (CC; 63.6%) patients with an average age of 46 over a lifetime horizon. The model assumed 61.6% of patients were GT1b; 24.2%, GT2; 8.1%, GT3; and, 6.1% GT6. CC patients accounted for 15.2% of GT1-2/6 and 21.3% for GT3. Model inputs were extrapolated from clinical trials, published literature, or expert opinion (Chinese-specific where possible). RESULTS: Across all genotypes, SOF+R led to the highest sustained virologic (SVR) rates

No abstract

No abstract